Related Experiment Video
Updated: Mar 13, 2026
12:58
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
9.4K
New and emerging therapies for Clostridium difficile infection
1aLeeds Teaching Hospitals NHS Trust/University of Leeds, Microbiology, Old Medical School, Leeds General Infirmary bLeeds Teaching Hospitals NHS Trust cUniversity of Leeds, Leeds dPublic Health England, UK.
Current Opinion in Infectious Diseases
|October 27, 2016
Summary
New treatments for Clostridium difficile infection (CDI) are emerging, including monoclonal antibodies, novel antibiotics, and microbiota-based therapies. These approaches aim to reduce recurrent CDI and improve patient outcomes.
Area of Science:
- Infectious Diseases
- Microbiology
- Immunology
Background:
- Clostridium difficile infection (CDI) presents a significant challenge to healthcare systems globally.
- High prevalence and impact on patients necessitate novel prevention and treatment strategies.
Purpose of the Study:
- To review current and emerging clinical trials for Clostridium difficile infection (CDI) prevention and treatment.
- To highlight promising new therapeutic and preventative approaches.
Main Methods:
- Review of phase II and III clinical trial data for various CDI interventions.
- Analysis of novel drug candidates, biologics, and vaccines targeting CDI.
Main Results:
- Bezlotoxumab, a monoclonal antibody, shows efficacy in reducing recurrent CDI when combined with antibiotics.
- Novel antibiotics (cadazolid, ridinilazole) and microbiota-based therapies (fecal microbiota transplantation variants, RBX2660, SER-109) are in development.
- A nontoxigenic C. difficile strain and three vaccines show promise for CDI prevention.
Conclusions:
- Diverse therapeutic and preventative strategies for CDI are advancing through clinical trials.
- Emerging treatments offer substantial promise for reducing CDI recurrence and improving patient management.
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
832
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
832
01:29Inflammatory Bowel Disease IV: Pharmacological Management
893
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
893
01:29Drugs for Treatment of Ulcerative Colitis in IBD
589
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
589
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
636
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
636
01:21Drugs for Treatment of Constipation-Predominant IBS
1.1K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.1K
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
1.8K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.8K